Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | Therapeutic potential of IdeS in hemophilia A with inhibitors

Melissa Bou Jaoudeh • 11 Jul 2022
ISTH 2022
Hemophilia Imlifidase

Melissa Bou Jaoudeh, PhD, Sorbonne University, Paris, France, comments on the therapeutic potential of imlifidase (IdeS) for the treatment of patients with hemophilia A with inhibitors, highlighting the results of an in vivo experiment using a humanized mouse model. The study showed that IdeS led to anti-factor VIII antibody elimination as well as recovery of factor VIII activity. In addition, subsequent injection of factor VIII led to a decrease in blood loss in a tail-clip bleeding model. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Melissa Bou Jaoudeh

Unmet needs in hemophilia: guidelines for emicizumab & better therapeutics for hemophilia A
1:36
Unmet needs in hemophilia: guidelines for emicizumab & better therapeutics for hemophilia A
Melissa Bou Jaoudeh • 11 Jul 2022
The impact of hemophilia inhibitors on patient outcomes
2:27
The impact of hemophilia inhibitors on patient outcomes
Melissa Bou Jaoudeh • 11 Jul 2022

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals